Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + triapine
- Development stage
- Phase 2
- Lead developer
- Eastern Cooperative Oncology Group
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Gemcitabine + triapine is an investigational combination therapy consisting of gemcitabine, a nucleoside analog, and triapine (3-AP), a ribonucleotide reductase inhibitor. The combination is designed to enhance gemcitabine's anticancer activity by preventing cancer cells from repairing DNA damage. Prolonged exposure to triapine followed by gemcitabine has shown potential to overcome gemcitabine resistance in some patients.
- Other names
- 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone + gemcitabine
02
Targets
DNA polymerase familyRRM2
Beyond the preview
Go deeper on gemcitabine + triapine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + triapine.